This is a StreetInsider.com Premium Only Page

(ELDN) –

Mar 28, 2024 05:12 PM Eledon Pharmaceuticals, Inc. (ELDN) Tops Q4 EPS by 4c

Mar 28, 2024 04:35 PM Form 10-K Eledon Pharmaceuticals, For: Dec 31

Mar 28, 2024 04:02 PM Form 8-K Eledon Pharmaceuticals, For: Mar 28

Mar 28, 2024 04:01 PM Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Mar 25, 2024 04:56 PM Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Mar 21, 2024 10:31 AM Eledon Pharmaceuticals (ELDN) Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

Mar 21, 2024 10:31 AM Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

Feb 14, 2024 03:36 PM Form SC 13G Eledon Pharmaceuticals, Filed by: ARMISTICE CAPITAL, LLC

Feb 14, 2024 03:02 PM Form SC 13G/A Eledon Pharmaceuticals, Filed by: Cormorant Asset Management, LP

Feb 14, 2024 10:08 AM Form SC 13G/A Eledon Pharmaceuticals, Filed by: BIOTECHNOLOGY VALUE FUND L P

Feb 13, 2024 07:01 PM Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 4, 2024 04:43 PM Eledon Pharmaceuticals (ELDN) Highlights Recent Business Milestones, Provides 2024 Outlook

Jan 4, 2024 04:40 PM Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

Dec 4, 2023 06:00 PM Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 29, 2023 04:05 PM Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference

Nov 29, 2023 04:05 PM Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference

Nov 9, 2023 06:25 PM Eledon Pharmaceuticals, Inc. (ELDN) Tops Q3 EPS by 8c

Nov 9, 2023 05:01 PM Form 10-Q Eledon Pharmaceuticals, For: Sep 30

Nov 9, 2023 04:06 PM Form 8-K Eledon Pharmaceuticals, For: Nov 09

Nov 9, 2023 04:01 PM Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

Nov 8, 2023 04:05 PM Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference

Nov 2, 2023 04:32 PM Form 8-K Eledon Pharmaceuticals, For: Nov 02

Nov 2, 2023 09:06 AM Eledon Pharmaceuticals (ELDN) Reports Updated Data from Ongoing Phase 1b Trial of Tegoprubart

Nov 2, 2023 09:05 AM Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Oct 24, 2023 06:36 AM Eledon Pharamceuticals (ELDN) PT Lowered to $13 at H.C. Wainwright

Oct 23, 2023 07:01 AM Eledon Pharmaceuticals (ELDN) Appoints Eliezer Katz as Chief Medical Officer

Oct 23, 2023 07:00 AM Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer

Oct 13, 2023 07:00 AM Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting

Oct 3, 2023 04:19 PM Form 4 Eledon Pharmaceuticals, For: Oct 02 Filed by: Robinson James A. Jr.

Oct 3, 2023 04:18 PM Form 4 Eledon Pharmaceuticals, For: Oct 02 Filed by: Kirk Allan

Oct 2, 2023 05:52 PM Form 3 Eledon Pharmaceuticals, For: Oct 01 Filed by: Robinson James A. Jr.

Oct 2, 2023 05:08 PM Form 3 Eledon Pharmaceuticals, For: Oct 02 Filed by: Kirk Allan

Oct 2, 2023 07:31 AM Form 8-K Eledon Pharmaceuticals, For: Sep 29

Oct 2, 2023 07:07 AM Eledon Pharmaceuticals (ELDN) Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors

Oct 2, 2023 07:00 AM Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors

Sep 27, 2023 07:36 AM Noble Capital Starts Eledon Pharamceuticals (ELDN) at Outperform

Sep 25, 2023 07:03 AM Eledon Pharmaceuticals (ELDN) Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human

Sep 25, 2023 07:00 AM Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human

Sep 21, 2023 06:03 AM Form 8-K Eledon Pharmaceuticals, For: Sep 20

Sep 20, 2023 04:05 PM Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference

Sep 13, 2023 04:42 PM Form 8-K Eledon Pharmaceuticals, For: Sep 11

Sep 11, 2023 07:02 AM Eledon Pharmaceuticals (ELDN) Appoints James Robinson to its Board

Sep 11, 2023 07:00 AM Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors

Sep 6, 2023 07:00 AM Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates

Sep 5, 2023 07:00 AM Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation

Aug 16, 2023 07:00 AM Eledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation

Aug 11, 2023 06:02 AM Form S-8 Eledon Pharmaceuticals,

Aug 10, 2023 05:01 PM Form 10-Q Eledon Pharmaceuticals, For: Jun 30

Aug 10, 2023 07:06 AM Form 8-K Eledon Pharmaceuticals, For: Aug 10

Aug 10, 2023 07:00 AM Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results